Axinn Granted Summary Judgment in Delaware Federal Court
June 24, 2014
Law360
A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.
Click here to read about the judgment in Law360’s article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
NBA Commercial Law Section 38th Annual Corporate Counsel Conference
Sponsorship
Antitrust
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
The 32nd Annual Marketing Partner Forum
Event
SABA North America Corporate Counsel Retreat 2025
Sponsorship
Antitrust
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
Client Alerts
Antitrust
Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
Awards & Recognitions
Antitrust
Merger Remedies Back in Vogue Under Trump
Media Mentions
Antitrust
Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
Axinn Viewpoints
Intellectual Property
A POSA’s Motivation Is Not Required To Be the Same as the Inventor’s in Evaluating Obviousness
Axinn Viewpoints
Intellectual Property